More on SMMT
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $17.30 |
|
|||
| Open | $17.73 | ||||
| 52 Wk High | $19.75 | ||||
| 52 Wk Low | $4.26 | ||||
| Day High | $18.10 | ||||
| Day Low | $17.42 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 3,628,561 | ||||
- UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
- Form 8-K Summit Therapeutics Inc. For: Sep 15
- Summit ivonescimab shows consistent survival data across regions at WCLC
- Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
- Form 8-K Summit Therapeutics Inc. For: Sep 13
- Ivonescimab cuts death risk 27% vs. pembrolizumab in lung cancer
- Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study
- Jefferies Upgrades Summit Therapeutics plc (SMMT) to Buy
- UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
- H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)
Entities mentioned with SMMT
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Equity Offerings | View Related Stories »
- Earnings | View Related Stories »
- S3 | View Related Stories »
- Show More...
